A possible reason to under-represent could be that Mayne Pharma's negotiations for Mithra products or licensing has been outbid by competitors.
I am sure if the money set aside for Mithra negotiations is no longer an option then a depressed share price is an awesome time for the board to resume our Share Buy Back and get a good discount doing it.
No one can complain as they have provided the market with an update albeit confusing but still have met continuous disclosure requirements.
MYX Price at posting:
$6.10 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)